Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Sight Sciences Unveils Ergo-Series for OMNI
Sight Sciences has launched the Ergo-Series of the OMNI Surgical System in the US, which is specifically designed to help surgeons in performing minimally invasive, implant-free glaucoma procedures in adults suffering from primary open-angle glaucoma. The OMNI Surgical System facilitates…
Benefits Of Combination Drops On Glaucoma Management
When patients are diagnosed with glaucoma, one of the most common treatment options is a prescription eye drop medication that lowers eye pressure, which prevents damage to the optic nerve and helps to preserve vision. Several types of drugs lower…
VSY Biotechnology Picks The Stars Of Ophthalmology
With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of…
A Next-Gen Monofocal IOL From Johnson & Johnson Vision
Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe TECNIS Eyhance™ Toric II IOL offers all the benefits associated with…
VSY Biotech Signs Agreement With WAKAMOTO Pharma
Leinfelden – Echterdingen, Germany March 19, 2021, VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
Alcon Signs $770 Million Deal to Acquire Aerie Pharma. I OBN
Swiss eye care company Alcon AG announced on Tuesday that it has entered into a definitive merger agreement with Aerie Pharmaceuticals (AERI.O) in a deal worth around $770 million. This deal complements Alcon’s dedication to the ophthalmic pharmaceutical industry and is…
Selagine and Grifols Team Up for DED Eye Drops
Selagine announced a global collaboration with Grifols to develop and commercialize immunoglobulin eye drops for dry eye disease. Financial terms of the agreement were not disclosed. As per the agreement, Selagine will receive an upfront payment and annual collaboration fee,…
Apotex Recalls Brimonidine Tartrate Ophthalmic Solution
Apotex Corp. has initiated a voluntary recall at the consumer level for 6 lots of brimonidine tartrate ophthalmic solution, 0.15%, distributed nationwide in the United States between April 5, 2022 to February 22, 2023 with the guidance of the US…
Akorn Pharmaceuticals Files for Bankruptcy
Akorn Pharmaceuticals, a maker of generic and branded drugs, has announced that it is ceasing operations business. The company, which provided over 20 ophthalmic products, has filed for chapter 7 bankruptcy, and will close all facilities in the United States. In…